Development, Validation, and Application of a Scoring Model for Non-alcoholic Steatohepatitis

被引:0
|
作者
Xiao, Jinfeng [1 ]
Zhang, Xinxin [1 ]
Zhu, Chonggui [1 ]
Gu, Yian [1 ]
Sun, Longhao [2 ]
Liang, Xiaoyu [2 ]
He, Qing [1 ]
机构
[1] Tianjin Med Univ Gen Hosp, Dept Endocrinol & Metab, 154 Anshan Rd, Tianjin 300052, Peoples R China
[2] Tianjin Med Univ Gen Hosp, Dept Gen Surg, Tianjin 300052, Peoples R China
关键词
Non-alcoholic liver disease; Non-alcoholic steatohepatitis; Non-invasive score; Sleeve gastrectomy; FATTY LIVER-DISEASE; MORBIDLY OBESE SUBJECTS; BARIATRIC SURGERY; PREVALENCE; PREDICTORS; FIBROSIS; SPECTRUM; SYSTEM; FEATURES;
D O I
10.1007/s11695-023-06804-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose The aim of this study was to explore risk factors of NASH and then develop a non-invasive scoring model in Chinese patients with obesity. A scoring system was then applied to assess the effect of sleeve gastrectomy on NASH.Methods A total of 243 patients with obesity were included and divided into NASH group and non-NASH group according to the pathological results of liver biopsy. Logistic regression was used to determine risk factors of NASH. A scoring model was derived by risk factors of NASH. Then, postoperative follow-up was performed in 70 patients.Results Among the 243 patients, 118 (48.56%) patients showed NASH. Multivariate logistic regression identified aspartate aminotransferase (AST) (>21.50 IU/L), high-density lipoprotein cholesterol (HDL-C) (<1.155mmol/L), and homeostasis model assessment (HOMA-IR) (>9.368) as independent risk factors of NASH. The model included above risk factors showed a negative predictive value (NPV) of 70.38% in the low-risk category and a positive predictive value (PPV) of 85.71% in the high-risk category, with the area under the receiver operator curve (AUROC) of 0.737. Bariatric surgery resulted in a sharp decline in AST and HOMA-IR and a significant increase of HDL-C. The points of scoring model were improved at 6 months after surgery.Conclusion A non-invasive scoring model was derived by the risk factors of NASH included AST, HDL-C, and HOMA-IR and applied to the postoperative follow-up. After sleeve gastrectomy, the above risk factors and points of scoring model were significantly improved.
引用
收藏
页码:3246 / 3255
页数:10
相关论文
共 50 条
  • [31] Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
    Povero, Davide
    Feldstein, Ariel E.
    [J]. DIABETES & METABOLISM JOURNAL, 2016, 40 (01) : 1 - 11
  • [32] Immunoregulation by lipids during the development of non-alcoholic steatohepatitis
    Ramadori, Pierluigi
    Kroy, Daniela
    Streetz, Konrad L.
    [J]. HEPATOBILIARY SURGERY AND NUTRITION, 2015, 4 (01) : 11 - 23
  • [33] Treatment of non-alcoholic steatohepatitis
    Angulo, P
    Lindor, KD
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 797 - 810
  • [34] Obesity and non-alcoholic steatohepatitis
    García-Monzón, C
    [J]. STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 117 - 123
  • [35] Drugs and non-alcoholic steatohepatitis
    Farrell, GC
    [J]. STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 132 - 139
  • [36] Selonsertib for non-alcoholic steatohepatitis
    Baker, Holly
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 852 - 852
  • [37] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    [J]. LANCET, 2001, 358 (9285): : 893 - 894
  • [38] Saroglitazar for non-alcoholic steatohepatitis
    Baker, Holly
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 698 - 698
  • [39] Mechanisms of non-alcoholic steatohepatitis
    McClain, CJ
    Mokshagundam, PL
    Barve, SS
    Song, ZY
    Hill, DB
    Chen, T
    Deaciuc, I
    [J]. ALCOHOL, 2004, 34 (01) : 67 - 79
  • [40] Fructose and Non-Alcoholic Steatohepatitis
    Roeb, Elke
    Weiskirchen, Ralf
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12